Arbutus Biopharma Logo
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
BWEN Logo.png
Broadwind Announces Third Quarter 2024 Results
November 13, 2024 07:00 ET | Broadwind, Inc.
CICERO, Ill., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today...
Optinose_logo_RGB.png
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
November 12, 2024 07:00 ET | Optinose, Inc.
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company...
TriumphFinancial_Logo_FullColor.png
Triumph Financial to Present at the Stephens Annual Investment Conference on November 19, in Nashville, Tennessee
November 08, 2024 16:07 ET | Triumph Financial, Inc.
DALLAS, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) today announced that Aaron Graft, Vice Chairman and CEO, will present at the Stephens Annual Investment Conference on...
liquidia-new-logo.png
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
November 06, 2024 08:00 ET | Liquidia Corporation
Liquidia Corporation (LQDA) to report its third quarter 2024 financial results on November 13, 2024, via webcast at 8:30 a.m. ET
Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024 07:30 ET | Arbutus Biopharma Corporation
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase...
Optinose_logo_RGB.png
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
November 05, 2024 16:30 ET | Optinose, Inc.
YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Logo_Pharming_original.png
Pharming Group to participate in November investor conference
November 05, 2024 02:00 ET | Pharming Group N.V.
Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
liquidia-new-logo.png
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
November 04, 2024 08:00 ET | Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA), to report its third quarter 2024 financial results via webcast at 8:30 a.m. ET on Friday, November 8, 2024.
MYR Group logo
MYR Group Inc. Announces Third-Quarter and First Nine-Months 2024 Results
October 30, 2024 16:05 ET | MYR Group, Inc.
THORNTON, Colo., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial...